HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

COO

The Cooper Companies, Inc. (S&P 500)

Healthcare — Medical Instruments & Supplies

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Buy 1.9 / 5 14 analysts
$72.06
+$1.77 (+2.52%)
Target: $81.21 (12.7%)
Sign in to add COO to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$14.05B
P/E Ratio (TTM)61.07
Forward P/E14.42
EPS (TTM)$1.18
Dividend Yield-
Profit Margin5.57%
Revenue Growth7.90%
ROE2.85%
Debt/Equity33.09
Recommendation Buy 1.9
Analyst Target$81.21
Analysts14
Indexes S&P 500

Technical Indicators

RSI (14)58.5
Beta0.84
SMA 20$71.25
SMA 40$68.81
52-Week High$89.83
52-Week Low$58.89
50-Day Avg$67.10
200-Day Avg$73.02
Avg Volume$2.91M
Volume$1.77M

Performance Analysis

BULLISH

COO shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 43% of its 52-week range.
+ RSI at 58.5 shows positive momentum.
- P/E of 61.1 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 7.9% year-over-year.
+ Wall Street consensus is "Buy" from 14 analysts.
+ Average analyst target of $81.21 implies 12.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:00 UTC

Back to Screener Export Report